Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corinna Eschbach

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Pneumologie (Stuttgart, Germany)|May 16, 2017
[Pain Management in Palliative Care]Martin B Steins, Corinna Eschbach, Matthias Villalobos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2013
Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancerPasi A Jänne, Luis Paz-Ares, Yun Oh, et al.
Lung Cancer (Amsterdam, Netherlands)|March 26, 2013
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancerDavid F Heigener, Joachim von Pawel, Corinna Eschbach, et al.
Oncology|January 25, 2012
A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancerJohan Vansteenkiste, Rodryg Ramlau, Joachim von Pawel, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 19, 2020
Severe symptoms and very low quality-of-life among outpatients newly diagnosed with advanced cancer: data from a multicenter cohort studyWaldemar Siemens, Stefan S Schönsteiner, Claudia Lorena Orellana-Rios, et al.
Clinical Lung Cancer|January 22, 2013
A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancerWolfgang H W Schuette, Andreas Gröschel, Martin Sebastian, et al.
Respiratory Medicine|October 13, 2009
Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in GermanyMartin Reck, Rolf A Stahel, Joachim von Pawel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II studyGiorgio V Scagliotti, Robert Ilaria, Silvia Novello, et al.
International Journal of Cancer|November 1, 2013
The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancerAkin Atmaca, Salah-Eddin Al-Batran, Ralph Markus Wirtz, et al.
The Lancet. Oncology|July 26, 2011
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX studyKenneth J O'Byrne, Ulrich Gatzemeier, Igor Bondarenko, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Pneumologie (Stuttgart, Germany)|May 16, 2017
[Pain Management in Palliative Care]Martin B Steins, Corinna Eschbach, Matthias Villalobos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2013
Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancerPasi A Jänne, Luis Paz-Ares, Yun Oh, et al.
Lung Cancer (Amsterdam, Netherlands)|March 26, 2013
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancerDavid F Heigener, Joachim von Pawel, Corinna Eschbach, et al.
Oncology|January 25, 2012
A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancerJohan Vansteenkiste, Rodryg Ramlau, Joachim von Pawel, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 19, 2020
Severe symptoms and very low quality-of-life among outpatients newly diagnosed with advanced cancer: data from a multicenter cohort studyWaldemar Siemens, Stefan S Schönsteiner, Claudia Lorena Orellana-Rios, et al.
Clinical Lung Cancer|January 22, 2013
A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancerWolfgang H W Schuette, Andreas Gröschel, Martin Sebastian, et al.
Respiratory Medicine|October 13, 2009
Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in GermanyMartin Reck, Rolf A Stahel, Joachim von Pawel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II studyGiorgio V Scagliotti, Robert Ilaria, Silvia Novello, et al.
International Journal of Cancer|November 1, 2013
The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancerAkin Atmaca, Salah-Eddin Al-Batran, Ralph Markus Wirtz, et al.
The Lancet. Oncology|July 26, 2011
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX studyKenneth J O'Byrne, Ulrich Gatzemeier, Igor Bondarenko, et al.
Pageof 1